BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based rare-disease specialist a market cap of roughly $2.5 billion. Shares are up 26.2% year to date and 18.6% over one year, though still down 35.3% over five years. What changed is the P&L
BioCryst notched its first full year of profitability in 2025, and Q2 2026 delivered $218.25 million in revenue, up 33.6% year over year, with $98.47 million in operating income and $352.57 million in cash, cash equivalents, and short-term investments. Mid-July takeover buzz following an acquisition in the biotech sector put BioCryst on watch lists, though no deal talks have been confirmed. Notably, BioCryst is itself an acquirer, having closed the Astria Therapeutics deal on January 23, 2026, to bring in navenibart.
Why a Strategic Buyer Would Want It
The prize is Orladeyo, an oral once-daily plasma kallikrein inhibitor for hereditary angioedema (HAE) that generated $158.2 million in Q2 2026 revenue, with full-year guidance of $625 million to $645 million. Behind it sits navenibart, a long-acting injectable whose pivotal ALPHA-ORBIT enrollment completed in June, with top-line data due Q3 2027. A European licensing deal with Neopharmed Gentili worth $70 million upfront plus up to $275 million in milestones already validated the asset
Ranking the Plausible Acquirers
5. Amgen (NASDAQ:AMGN | AMGN Price Prediction). The Horizon playbook fits, but Amgen carries $57.3 billion in debt and a Tavneos withdrawal overhang, limiting appetite
4. Sanofi (NASDAQ:SNY). Deep rare-disease bench and a fresh $2.2 billion Dynavax acquisition, but focus is Dupixent and immunology under a new CEO
3. Novartis (NYSE:NVS). The Swiss multinational has an HAE-adjacent complement in Fabhalta, but a deal could trigger antitrust scrutiny
2. AstraZeneca (NASDAQ:AZN). Alexion has turned rare disease into a $2.42 billion Q1 2026 franchise, up 19%. HAE would slot cleanly beside Ultomiris and Strensiq. Risk: management is focused on oncology and China business development, not HAE
1. Takeda Pharmaceutical (NYSE:TAK). Takeda’s Takhzyro is the incumbent HAE injectable that navenibart directly threatens. The defensive consolidation logic is strongest here, though a net debt/EBITDA ratio of 2.7x restricts large checks
What About Private Equity?
BioCryst screens well for a take-private: recurring Orladeyo cash flow, 45.1% operating margin, and a manageable $2.40 billion equity check. The hitch is negative shareholders’ equity of $454.29 million and roughly $822 million in combined term-loan and royalty obligations. Sponsors also rarely outbid a strategic chasing a scarce HAE franchise, so PE ranks below Takeda and AstraZeneca in the pecking order
What to Watch
Analysts are positive on BioCryst and have a consensus target of $20.82. The full-chain put/call ratio is 0.11, skewed heavily toward calls. CEO Charlie Gayer had this to say: “We were pleased to deliver strong revenue growth and positive free cash flow again in the second quarter.” Watch the stock ahead of navenibart readouts and any 13D activity
Contact [email protected] for any questions or corrections
